ARTICLE | Company News

Praecis cancer, neurology news

May 23, 2005 7:00 AM UTC

PRCS also will suspend clinical development and look to partner Apan, a beta amyloid 5-amino acid inhibitor that is in a Phase I/IIa trial to treat Alzheimer's disease. PRCS will continue to develop its PPI-2458 methionine aminopeptidase 2 (MetAP2) inhibitor, which is in Phase I testing to treat non-Hodgkin's lymphoma (NHL) and solid tumors. The company also will continue to develop its Direct Select drug discovery technology. ...